If you don’t have access to the full text of this review in Lancet Infectious Diseases Medscape has a nice summary with CME credit (non-industry supported).
For multi-drug resistant infections tygecycline and the polymyxins show the most promise. Carbapenems are effective in most infections but rising resistance is a concern. Data from clinical trials are scant.
No comments:
Post a Comment